drugset / Trial / NCT01924767

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets

NCT01924767

Phase 1 Completed 48 enrolled Boehringer Ingelheim
RandomizedSingle-groupDouble-blindTreatment

Summary

To investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 10773 with repeat dosing for eight days and the exploration of the pharmacokinetics and pharmacodynamics of BI 10773 after multiple dosing, including dose proportionality and assessment of steady state.

Timeline

Start
2007-07
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule Oral